 Matinas BioPharma Holdings Inc NYSE: MTNB has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 oral amphotericin B for cryptococcal meningitis. The study is sponsored by the National Institute of Allergy and Infectious Diseases NIAID. 